Alphaonco

France

Back to Profile

1-35 of 35 for Alphaonco Sort by
Query
Aggregations
Jurisdiction
        United States 25
        Canada 10
Date
New (last 4 weeks) 1
2026 June (MTD) 1
2026 (YTD) 1
2025 2
2024 5
See more
IPC Class
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation 20
A61K 9/51 - Nanocapsules 12
A61K 33/26 - IronCompounds thereof 11
A61K 35/74 - Bacteria 11
A61N 2/00 - Magnetotherapy 8
See more
Status
Pending 14
Registered / In Force 21
Found results for  patents

1.

INTERFERENCE SYSTEM COMPRISING AT LEAST TWO SOURCES OF RADIATION EMITTING TWO BEAMS OF RADIATION INTERFERING IN A BODY PART OR REGION TO BE TREATED AND AT LEAST ONE NANOPARTICLE

      
Application Number 19403345
Status Pending
Filing Date 2025-11-28
First Publication Date 2026-06-04
Owner ALPHAONCO (France)
Inventor Alphandéry, Edouard

Abstract

A radiation heating system that includes at least two orientated radiation emitting elements that emit at least two radiation beams. There is a treated region of interference of the at least two radiation beams emitted by the at least two radiation emitting elements. The system also includes at least one nanoparticle comprised in the interference region.

IPC Classes  ?

  • A61N 7/02 - Localised ultrasound hyperthermia

2.

CRYOSYSTEM COMPRISING NANOPARTICLES FOR TREATING A BODY PART OF AN INDIVIDUAL BY CRYOTHERAPY

      
Application Number 18918358
Status Pending
Filing Date 2024-10-17
First Publication Date 2025-01-30
Owner AlphaOnco (France)
Inventor
  • Alphandéry, Edouard
  • Li-Soulisse, Sha

Abstract

A cryo-system for treating a body part of an individual by cryotherapy, which includes two parts. The first part is either i) a cryo-probe suitable for internal cooling, which includes a penetrating segment in communication with a cryogen source and is at least smaller than 1/10th of the body part's biggest volume and/or at least one dimension smaller than 1 cm or ii) a cryo-probe suitable for external cooling, which includes a non-penetrating segment in communication with a cryogen source. The second part is either i) an assembly of at least two nanoparticles bound to each other or associated with each other via binding or associating material or ii) at least one nanoparticle, which includes iron and at least one other metal than iron. The assembly of at least two nanoparticles or the at least one nanoparticle may be cooled by the cryo-probe or by switching on the cryo-probe.

IPC Classes  ?

  • A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
  • A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61F 7/12 - Devices for heating or cooling internal body cavities

3.

METHOD FOR REMOVING IMPURITIES FROM NANOPARTICLES

      
Application Number 18895634
Status Pending
Filing Date 2024-09-25
First Publication Date 2025-01-16
Owner AlphaOnco (France)
Inventor Alphandery, Edouard

Abstract

A method for removing at least one impurity from metal-based nanoparticles, including at least two heating steps. During step 1, the temperature of the nanoparticles is increased to a temperature T1, and is then maintained at T1 during a heating time that is included between 1 second and 20 years, where T1 is included between 50° C. and 300° C. During step 2, the temperature of the nanoparticles is increased to a temperature T2, and is then maintained at T2 during a heating time that is included between 1 second and 20 years, where T2 is included between 300° C. and 600° C.

IPC Classes  ?

4.

CELLULAR PRODUCTION OF PURE IRON OXIDE NANOPARTICLES

      
Application Number 18340297
Status Pending
Filing Date 2023-06-23
First Publication Date 2024-07-11
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

High purity magnetosomes produced by magnetotactic bacteria, wherein the metallic composition of the magnetosome is characterized by a high level of iron purity, preferentially not achieved through a chemical synthesis. The high purity magnetosomes are further characterized by having a content of Cd, Pb, Ni, Co, Al, Mn, Zn, Li, and/or Cu.

IPC Classes  ?

  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
  • A61K 33/24 - Heavy metalsCompounds thereof
  • A61K 33/241 - LeadCompounds thereof
  • A61K 33/30 - ZincCompounds thereof
  • A61K 33/32 - ManganeseCompounds thereof
  • A61K 33/34 - CopperCompounds thereof

5.

NANOPARTICLES SEQUENTIALLY EXPOSED TO LOW INTENSITY ACOUSTIC WAVES FOR MEDICAL OR COSMETIC APPLICATIONS

      
Application Number 18422687
Status Pending
Filing Date 2024-01-25
First Publication Date 2024-06-20
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard Alexander

Abstract

An acoustic wave medical treatment of a body part of an individual in which nanoparticles are administered to the body part of the individual and the acoustic wave is applied on the body part, and the system for performing the treatment. The acoustic wave is sequentially applied on the body part, and/or the nanoparticles are magnetosomes. Also, the compositions that include these nanoparticles.

IPC Classes  ?

  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body
  • A61K 9/50 - Microcapsules
  • A61K 33/26 - IronCompounds thereof
  • A61N 7/02 - Localised ultrasound hyperthermia
  • A61P 35/00 - Antineoplastic agents

6.

METHOD TO ENABLE NANOPARTICLES STORED WITH A SPECIFIC TYPE OF ASSEMBLY TO MAINTAIN THIS TYPE OF ASSEMBLY UPON RECONSTITUTION

      
Application Number 18509901
Status Pending
Filing Date 2023-11-15
First Publication Date 2024-05-23
Owner ALPHAONCO (France)
Inventor Alphandéry, Edouard

Abstract

A composition including at least one nanoparticle or at least one chain of at least two nanoparticles, wherein each nanoparticle in the chain preferentially includes an iron oxide mineral core preferentially surrounded by a coating, wherein the composition further includes a cryo-protectant or protectant compound, wherein the volume occupied by the cryo-protectant or protectant compound in the composition is preferentially larger than the volume occupied by at least one chain in the composition, preferentially by a factor of at least 1, 2, 5, 10 or 103, wherein the percentage in mass of cryo-protectant or protectant compound in the composition is preferentially between 0.5 and 50%, wherein the composition is preferentially isotonic.

IPC Classes  ?

  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 9/50 - Microcapsules
  • A61K 9/51 - Nanocapsules

7.

IRON OXIDE NANOPARTICLES COMPRISING TWO CENTERS OF ACTIVITIES OR FREE RADICAL CAPTURE/PRODUCTION FOR AN ENHANCED ACTIVITY AND COMBINING SPATIAL AND TEMPORAL SEQUENCES OF IRRADIATION USING THE NANOPARTICLES FOR AN IMPROVED TREATMENT OF DISEASES

      
Application Number 18509909
Status Pending
Filing Date 2023-11-15
First Publication Date 2024-05-16
Owner ALPHAONCO (France)
Inventor Alphandéry, Edouard

Abstract

A composition including nanoparticle(s) having an iron oxide mineral core surrounded by a coating and a cryo-protectant. The core includes a first center activity and/or the coating includes a second center of activity, each of which are either: (A) a radio sensitizer/amplifier of radiation, an acoustic sensitizer/amplifier of acoustic radiation, a sonosensitizer/amplificatory of acoustic wave, a particle radiation sensitizer/amplifier of particle radiation; or (B) an attenuator of radiation, of light radiation, of acoustic radiation or wave, of particle radiation. Also a method of using the composition for increasing production of free radicals or amplifying radiation during a sonodynamic, photodynamic or radiation therapy or exposure of a body part to a radiation in the treatment of diseases.

IPC Classes  ?

  • A61K 9/51 - Nanocapsules
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

8.

A METHOD TO ENABLE NANOPARTICLES STORED WITH A SPECIFIC TYPE OF ASSEMBLY TO MAINTAIN THIS TYPE OF ASSEMBLY UPON RECONSTITUTION

      
Document Number 03220038
Status Pending
Filing Date 2023-11-14
Open to Public Date 2024-05-15
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Chebbi, Imene

Abstract

The invention relates to a composition comprising at least one nanoparticle or at least one chain of at least two nanoparticles, wherein each nanoparticle in the chain preferentially comprises an iron oxide mineral core preferentially surrounded by a coating, wherein the composition further comprises a cry o-protectant or protectant compound, wherein the volume occupied by the cryo-protectant or protectant compound in the composition is preferentially larger than the volume occupied by at least one chain in the composition, preferentially by a factor of at least 1, 2, 5, 10 or 103, wherein the percentage in mass of cryo-protectant or protectant compound in the composition is preferentially comprised between 0.5 and 50 %, wherein the composition is preferentially isotonic.

IPC Classes  ?

9.

Cryosystem comprising nanoparticles for treating a body part of an individual by cryotherapy

      
Application Number 18298801
Grant Number 12150689
Status In Force
Filing Date 2023-04-11
First Publication Date 2023-08-03
Grant Date 2024-11-26
Owner ALPHAONCO (France)
Inventor
  • Alphandéry, Edouard
  • Li-Soulisse, Sha

Abstract

A cryo-system for treating a body part of an individual by cryotherapy, which includes two parts. The first part is either i) a cryo-probe suitable for internal cooling, which includes a penetrating segment in communication with a cryogen source and is at least smaller than 1/10th of the body part's biggest volume and/or at least one dimension smaller than 1 cm or ii) a cryo-probe suitable for external cooling, which includes a non-penetrating segment in communication with a cryogen source. The second part is either i) an assembly of at least two nanoparticles bound to each other or associated with each other via binding or associating material or ii) at least one nanoparticle, which includes iron and at least one other metal than iron. The assembly of at least two nanoparticles or the at least one nanoparticle may be cooled by the cryo-probe or by switching on the cryo-probe.

IPC Classes  ?

  • A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
  • A61F 7/12 - Devices for heating or cooling internal body cavities
  • A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body

10.

Magnetic field or radiation oscillating at several frequencies for improving efficacy and/or reducing toxicity of magnetic hyperthermia

      
Application Number 18147952
Grant Number 12521563
Status In Force
Filing Date 2022-12-29
First Publication Date 2023-05-11
Grant Date 2026-01-13
Owner AlphaOnco (France)
Inventor Alphandéry, Edouard

Abstract

Magnetic nanoparticles for use in a magnetic hyperthermia therapeutic treatment, prophylactic treatment, cosmetic treatment or diagnosis method, wherein the magnetic nanoparticles are administered to a body part of an individual and the body part is exposed to a magnetic field or radiation oscillating at a high frequency and at a medium and/or low frequency, wherein the high frequency is 1 MHz at the most, the medium frequency is lower than the high frequency, and the low frequency is lower than the high frequency and lower than the medium frequency when it is present.

IPC Classes  ?

  • A61N 1/40 - Applying electric fields by inductive or capacitive coupling
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

11.

METHOD FOR INCREASING THE RELEASE OF MEDICAL COMPOUNDS FROM NANOPARTICLES BY AN ALTERATION STEP AND A PHYSICO-CHEMICAL DISTURBANCE STEP

      
Application Number 17605383
Status Pending
Filing Date 2020-04-23
First Publication Date 2022-07-28
Owner ALPHAONCO (France)
Inventor Alphandéry, Edouard

Abstract

A method for increasing the release of at least one compound, the compound being initially an initial compound bound to at least one initial nanoparticle, the initial compound bound to the initial nanoparticle forming an initial particle, wherein the initial particle includes at least one active ingredient, the method including at least one step of alteration of the initial particle and at least one step of physico-chemical disturbance of an altered particle resulting from the alteration.

IPC Classes  ?

  • A61K 49/00 - Preparations for testing in vivo
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

12.

PARTICLE COMPRISING AT LEAST ONE FERRIMAGNETIC OR FERROMAGNETIC IRON OXIDE NANOPARTICLE ASSOCIATED WITH AT LEAST ONE COMPOUND FOR MEDICAL OR COSMETIC USE

      
Application Number 17245504
Status Pending
Filing Date 2021-04-30
First Publication Date 2021-08-26
Owner ALPHAONCO (France)
Inventor
  • Alphandéry, Edouard
  • Chebbi, Imène

Abstract

The use, especially in vitro, of a particle including at least one ferrimagnetic or ferromagnetic iron oxide nanoparticle associated with at least one compound, in which the compound dissociates from the at least one ferrimagnetic or ferromagnetic iron oxide nanoparticle and/or chemically modifies itself, following a physicochemical disturbance applied on the particle, as a probe.

IPC Classes  ?

  • C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
  • G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
  • A61K 9/51 - Nanocapsules
  • C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide

13.

Non-pyrogenic preparation comprising nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications

      
Application Number 17198645
Grant Number 11759478
Status In Force
Filing Date 2021-03-11
First Publication Date 2021-07-01
Grant Date 2023-09-19
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Durand-Dubief, Mickael

Abstract

A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria.

IPC Classes  ?

  • A61K 33/26 - IronCompounds thereof
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
  • A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K 8/25 - SiliconCompounds thereof
  • A61K 8/26 - AluminiumCompounds thereof
  • A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
  • A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
  • A61K 8/73 - Polysaccharides
  • A61K 8/85 - Polyesters
  • A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
  • A61K 9/51 - Nanocapsules
  • A61K 35/74 - Bacteria
  • A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
  • A61L 31/02 - Inorganic materials
  • A61L 31/08 - Materials for coatings
  • A61L 31/10 - Macromolecular materials
  • A61Q 19/00 - Preparations for care of the skin
  • G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH

14.

A CRYOSYSTEM COMPRISING NANOPARTICLES FOR TREATING A BODY PART OF AN INDIVIDUAL BY CRYOTHERAPY

      
Document Number 03082149
Status Pending
Filing Date 2020-05-29
Open to Public Date 2020-12-03
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Li-Soulisse, Sha

Abstract

The invention relates to a cry o-system for treating a body part of an individual by cryotherapy comprising two parts:a) a first part, which is a cryo-probe wherein:i) the cryo-probe is suitable for an internal cooling action as it comprises a penetrating segment which is in communication with a cryogen source and which is at least smaller than 1/10th of the biggest volume of said body part and/or has at least one dimension smaller than 1 cm;orii) the cryo-probe is suitable for an external cooling action as it comprises a non-penetrating segmentin communication with a cryogen source,andb) a second part, which is either:i) an assembly of at least two nanoparticles characterized in that this assembly comprises at least two nanoparticles bound to each other or associated with each other via binding or associating material, orii) at least one nanoparticle that comprises iron and at least one other metal than iron, wherein the assembly of at least two nanoparticles or the at least one nanoparticle is meant to be cooled down by the cryo-probe or by switching on the cryo-probe.

IPC Classes  ?

  • A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques

15.

Cryosystem comprising nanoparticles for treating a body part of an individual by cryotherapy

      
Application Number 16887179
Grant Number 11744629
Status In Force
Filing Date 2020-05-29
First Publication Date 2020-12-03
Grant Date 2023-09-05
Owner ALPHAONCO (France)
Inventor
  • Alphandéry, Edouard
  • Li-Soulisse, Sha

Abstract

A cryo-system for treating a body part of an individual by cryotherapy, which includes two parts. The first part is either i) a cryo-probe suitable for internal cooling, which includes a penetrating segment in communication with a cryogen source and is at least smaller than 1/10th of the body part's biggest volume and/or at least one dimension smaller than 1 cm or ii) a cryo-probe suitable for external cooling, which includes a non-penetrating segment in communication with a cryogen source. The second part is either i) an assembly of at least two nanoparticles bound to each other or associated with each other via binding or associating material or ii) at least one nanoparticle, which includes iron and at least one other metal than iron. The assembly of at least two nanoparticles or the at least one nanoparticle may be cooled by the cryo-probe or by switching on the cryo-probe.

IPC Classes  ?

  • A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
  • A61F 7/12 - Devices for heating or cooling internal body cavities
  • A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
  • A61F 7/00 - Heating or cooling appliances for medical or therapeutic treatment of the human body

16.

METHOD FOR INCREASING THE RELEASE OF MEDICAL COMPOUNDS FROM NANOPARTICLES BY AN ALTERATION STEP AND A PHYSICO-CHEMICAL DISTURBANCE STEP

      
Document Number 03136792
Status In Force
Filing Date 2020-04-23
Open to Public Date 2020-10-29
Grant Date 2025-10-14
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

The present invention relates to a method for increasing the release of at least one compound, said compound being initially an initial compound bound to at least one initial nanoparticle, said initial compound bound to said initial nanoparticle forming an initial particle, wherein the initial particle comprises at least one active ingredient, said method comprising at least one step of alteration of the initial particle and at least one step of physico-chemical disturbance of an altered particle resulting from the alteration.

IPC Classes  ?

  • A61K 9/51 - Nanocapsules
  • A61K 33/26 - IronCompounds thereof
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 47/02 - Inorganic compounds
  • A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 49/00 - Preparations for testing in vivo
  • A61P 35/00 - Antineoplastic agents

17.

Magnetic nanoparticles for destroying pathological cells in an individual

      
Application Number 16845412
Grant Number 11369699
Status In Force
Filing Date 2020-04-10
First Publication Date 2020-07-30
Grant Date 2022-06-28
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

A composition including magnetic nanoparticles for use in the treatment of a tissue volume including pathological cells in an individual, wherein a portion only of the tissue volume is occupied by the magnetic nanoparticles upon administration of the composition to the individual and the magnetic nanoparticles are excited by radiation.

IPC Classes  ?

  • A61N 2/00 - Magnetotherapy
  • A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
  • A61K 35/74 - Bacteria
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 33/26 - IronCompounds thereof
  • A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
  • A61N 1/40 - Applying electric fields by inductive or capacitive coupling
  • A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
  • A61N 5/00 - Radiation therapy
  • B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

18.

CELLULAR PRODUCTION OF PURE IRON OXIDE NANOPARTICLES

      
Document Number 03057346
Status Pending
Filing Date 2019-10-01
Open to Public Date 2020-04-02
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

A method for producing high purity iron oxide nanoparticles using nanoparticle-producing cells, including: a) a pre-growth step that includes amplifying the nanoparticle-producing cell(s) in a pre-growth and/or fed-batch medium/media, and b) a growth step that includes amplifying the nanoparticle-producing cell(s) originating from the pre-growth step in a growth and/or fed-batch medium/media, wherein the pre-growth and/or growth and/or fed-batch medium/media comprise(s), per kilogram or liter of pre-growth and/or growth and/or fed-batch medium/media: i) no more than 0.005 gram of yeast extract, and ii) no more than 0.001 gram of CMR agent selected from boric acid and nitrilotriacetic acid, wherein the fed-batch medium when it is present is a medium that supplements the pre-growth and/or growth medium/media, and wherein more nanoparticles are produced in the growth step than in the pre-growth step.

IPC Classes  ?

  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 35/74 - Bacteria
  • C01G 49/02 - OxidesHydroxides
  • C04B 35/26 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on ferrites
  • C04B 35/622 - Forming processesProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products
  • C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide

19.

Cellular production of pure iron oxide nanoparticles

      
Application Number 16589227
Grant Number 11732277
Status In Force
Filing Date 2019-10-01
First Publication Date 2020-04-02
Grant Date 2023-08-22
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

A method for producing high purity iron oxide nanoparticles using nanoparticle-producing cells, including: a) a pre-growth step that includes amplifying the nanoparticle-producing cell(s) in a pre-growth and/or fed-batch medium/media, and b) a growth step that includes amplifying the nanoparticle-producing cell(s) originating from the pre-growth step in a growth and/or fed-batch medium/media, wherein the pre-growth and/or growth and/or fed-batch medium/media comprise(s), per kilogram or liter of pre-growth and/or growth and/or fed-batch medium/media: i) no more than 0.005 gram of yeast extract, and ii) no more than 0.001 gram of CMR agent selected from boric acid and nitrilotriacetic acid, wherein the fed-batch medium when it is present is a medium that supplements the pre-growth and/or growth medium/media, and wherein more nanoparticles are produced in the growth step than in the pre-growth step.

IPC Classes  ?

  • C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
  • C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
  • C12N 1/20 - BacteriaCulture media therefor
  • C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
  • B82Y 35/00 - Methods or apparatus for measurement or analysis of nanostructures
  • B82Y 40/00 - Manufacture or treatment of nanostructures

20.

Method for removing impurities from nanoparticles

      
Application Number 16589394
Grant Number 12129502
Status In Force
Filing Date 2019-10-01
First Publication Date 2020-04-02
Grant Date 2024-10-29
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

2 is included between 300° C. and 600° C.

IPC Classes  ?

  • C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
  • B82Y 35/00 - Methods or apparatus for measurement or analysis of nanostructures
  • B82Y 40/00 - Manufacture or treatment of nanostructures
  • C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
  • C12N 1/20 - BacteriaCulture media therefor
  • C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound

21.

Nanoparticles sequentially exposed to low intensity acoustic waves for medical or cosmetic applications

      
Application Number 16486574
Grant Number 11918652
Status In Force
Filing Date 2018-11-29
First Publication Date 2020-01-02
Grant Date 2024-03-05
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

An acoustic wave medical treatment of a body part of an individual in which nanoparticles are administered to the body part of the individual and the acoustic wave is applied on the body part. The acoustic wave is sequentially applied on the body part, and/or the nanoparticles are magnetosomes. Also, compositions that include these nanoparticles.

IPC Classes  ?

  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61N 7/02 - Localised ultrasound hyperthermia
  • G01N 29/09 - Analysing solids by measuring mechanical or acoustic impedance
  • G01N 29/11 - Analysing solids by measuring attenuation of acoustic waves

22.

Magnetic nanoparticles sequentially irradiated by laser radiation for medical or chemical or biological or cosmetic applications

      
Application Number 16412933
Grant Number 11571393
Status In Force
Filing Date 2019-05-15
First Publication Date 2019-11-21
Grant Date 2023-02-07
Owner ALPHAONCO (France)
Inventor Alphandéry, Edouard

Abstract

Magnetosomes for use in a sequential laser radiation medical treatment, wherein the magnetosomes are administered to a body part of an individual. In a first step, the magnetosomes are irradiated by a laser radiation, and in a second step, the magnetosomes are irradiated by a laser radiation of lower power than in the first step or no laser irradiation of the magnetosomes is performed. The sequence of the first step and second step is repeated at least once.

IPC Classes  ?

  • A61N 2/00 - Magnetotherapy
  • A61K 9/50 - Microcapsules
  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
  • B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
  • B82Y 25/00 - Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
  • H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

23.

MAGNETIC NANOPARTICLES SEQUENTIALLY IRRADIATED BY LASER RADIATION FOR MEDICAL OR CHEMICAL OR BIOLOGICAL OR COSMETIC APPLICATIONS

      
Document Number 03043592
Status Pending
Filing Date 2019-05-15
Open to Public Date 2019-11-16
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

This invention relates magnetosomes in a sequential laser radiation medical or biological or chemicalor cosmetic treatment, wherein the magnetosomes are administered to a body part of an individualand:- In a first step, the magnetosomes are irradiated by a laser radiation at a first power, and- In a second step, the magnetosomes are irradiated by a laser radiation of lower power than in the firststep or no laser irradiation of the magnetosomes is performed, andthe sequence comprising the first step and the second step is repeated at least once.

IPC Classes  ?

  • A61K 35/74 - Bacteria
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 49/00 - Preparations for testing in vivo
  • A61N 5/067 - Radiation therapy using light using laser light
  • C01G 49/02 - OxidesHydroxides
  • C01G 49/12 - Sulfides
  • C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

24.

Non-pyrogenic preparation comprising nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications

      
Application Number 16506104
Grant Number 10980833
Status In Force
Filing Date 2019-07-09
First Publication Date 2019-10-31
Grant Date 2021-04-20
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Durand-Dubief, Mickael

Abstract

A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria.

IPC Classes  ?

  • A61K 33/26 - IronCompounds thereof
  • C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
  • A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
  • A61K 8/73 - Polysaccharides
  • A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
  • A61K 9/51 - Nanocapsules
  • A61K 35/74 - Bacteria
  • A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
  • A61L 31/02 - Inorganic materials
  • A61L 31/08 - Materials for coatings
  • A61L 31/10 - Macromolecular materials
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 8/25 - SiliconCompounds thereof
  • A61K 8/26 - AluminiumCompounds thereof
  • A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
  • A61K 8/85 - Polyesters
  • A61Q 19/00 - Preparations for care of the skin
  • G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH

25.

Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field

      
Application Number 16292662
Grant Number 10974059
Status In Force
Filing Date 2019-03-05
First Publication Date 2019-07-04
Grant Date 2021-04-13
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Faure, Stephanie
  • Chebbi, Imene

Abstract

A method for the treatment of tumor(s) or tumor cell(s) or cancer(s) in a subject in need by the generation of heat. The latter is produced by chains of magnetosomes extracted from whole magnetotactic bacteria and subjected to an alternating magnetic field. These chains of magnetosomes yield efficient antitumoral activity whereas magnetosomes unbound from the chains or kept within the whole bacteria produce poor or no antitumoral activity. The introduction of various chemicals such as chelating agents and/or transition metals within the growth medium of the bacteria improves the heating properties of the chains of magnetosomes. Moreover, the insertion of the chains of magnetosomes within a lipid vesicle is also suggested in order to favor their rotation in vivo and hence to improve their heating capacity. The vesicle can contain an antitumoral agent together with the chains of magnetosomes. In this case, the agent is released within the tumors by heating the vesicle.

IPC Classes  ?

  • A61N 1/40 - Applying electric fields by inductive or capacitive coupling
  • A61N 2/00 - Magnetotherapy
  • A61K 35/74 - Bacteria
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • C12N 1/20 - BacteriaCulture media therefor
  • C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/10 - DispersionsEmulsions
  • A61K 9/51 - Nanocapsules
  • A61K 33/26 - IronCompounds thereof

26.

Magnetic field oscillating at several frequencies for improving efficacy and/or reducing toxicity of magnetic hyperthermia

      
Application Number 16325486
Grant Number 11633616
Status In Force
Filing Date 2018-02-12
First Publication Date 2019-06-27
Grant Date 2023-04-25
Owner ALPHAONCO (France)
Inventor Alphandéry, Edouard

Abstract

Magnetic nanoparticles for use in a magnetic hyperthermia therapeutic treatment, prophylactic treatment or diagnosis method, wherein the magnetic nanoparticles are administered to a body part of an individual and the body part is exposed to a magnetic field oscillating at a high frequency and at a medium and/or low frequency, wherein the high frequency is 1 MHz at the most, the medium frequency is lower than the high frequency, and the low frequency is lower than the high frequency and lower than the medium frequency when it is present.

IPC Classes  ?

  • A61N 1/40 - Applying electric fields by inductive or capacitive coupling
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61N 2/00 - Magnetotherapy

27.

NANOPARTICLES SEQUENTIALLY EXPOSED TO LOW INTENSITY ACOUSTIC WAVES FOR MEDICAL OR COSMETIC APPLICATIONS

      
Document Number 03050088
Status Pending
Filing Date 2018-11-29
Open to Public Date 2019-06-06
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

This invention relates to nanoparticles for use in an acoustic wave medical treatment of a body part of an individual, wherein nanoparticles are administered to the body part of the individual and the acoustic wave is applied on the body part, wherein the acoustic wave is sequentially applied on the body part, and/or, the nanoparticles are magnetosomes.

IPC Classes  ?

  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61P 35/00 - Antineoplastic agents

28.

MAGNETIC FIELD OSCILLATING AT SEVERAL FREQUENCIES FOR IMPROVING EFFICACY AND/OR REDUCING TOXICITY OF MAGNETIC HYPERTHERMIA

      
Document Number 03030632
Status In Force
Filing Date 2018-02-12
Open to Public Date 2018-08-23
Grant Date 2021-06-01
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

This invention concerns magnetic nanoparticles for use in a magnetic hyperthermia therapeutic treatment, prophylactic treatment or diagnosis method, wherein the magnetic nanoparticles are administered to a body part of an individual and the body part is exposed to a magnetic field oscillating at a high frequency and at a medium and/or low frequency, wherein the high frequency is 1 MHz at the most, the medium frequency is lower than the high frequency, and the low frequency is lower than the high frequency and lower than the medium frequency when it is present.

IPC Classes  ?

  • A61N 1/40 - Applying electric fields by inductive or capacitive coupling
  • A61N 2/00 - Magnetotherapy

29.

Magnetic nanoparticles for destroying pathological cells in an individual

      
Application Number 15615206
Grant Number 10660975
Status In Force
Filing Date 2017-06-06
First Publication Date 2018-04-26
Grant Date 2020-05-26
Owner ALPHAONCO (France)
Inventor Alphandery, Edouard

Abstract

Disclosed is a composition including magnetic nanoparticles for use in the treatment of a tissue volume including pathological cells in an individual, wherein a portion only of the tissue volume is occupied by the magnetic nanoparticles upon administration of the composition to the individual and the magnetic nanoparticles are excited by radiations.

IPC Classes  ?

  • A61N 2/00 - Magnetotherapy
  • A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
  • A61K 35/74 - Bacteria
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K 33/26 - IronCompounds thereof
  • A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
  • A61N 1/40 - Applying electric fields by inductive or capacitive coupling
  • A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
  • A61N 5/00 - Radiation therapy
  • B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

30.

Non-pyrogenic preparation comprising nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications

      
Application Number 15510048
Grant Number 10391122
Status In Force
Filing Date 2016-06-15
First Publication Date 2017-10-19
Grant Date 2019-08-27
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Durand-Dubief, Mickael

Abstract

A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria.

IPC Classes  ?

  • A61K 33/26 - IronCompounds thereof
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
  • A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K 8/25 - SiliconCompounds thereof
  • A61K 8/26 - AluminiumCompounds thereof
  • A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
  • A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
  • A61K 8/73 - Polysaccharides
  • A61K 8/85 - Polyesters
  • A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
  • A61K 9/51 - Nanocapsules
  • A61K 35/74 - Bacteria
  • A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
  • A61L 31/02 - Inorganic materials
  • A61L 31/08 - Materials for coatings
  • A61L 31/10 - Macromolecular materials
  • A61Q 19/00 - Preparations for care of the skin
  • G01N 33/84 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving inorganic compounds or pH

31.

Treatment of cancer or tumor induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field

      
Application Number 15433018
Grant Number 10252073
Status In Force
Filing Date 2017-02-15
First Publication Date 2017-06-08
Grant Date 2019-04-09
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Faure, Stéphanie
  • Chebbi, Imène

Abstract

A method for the treatment of tumor(s), tumor cell(s), cancer(s) in a subject by the generation of heat. The latter is produced by chains of magnetosomes extracted from whole magnetotactic bacteria and subjected to an alternating magnetic field. These chains of magnetosomes yield efficient antitumoral activity whereas magnetosomes unbound from the chains or kept within the whole bacteria produce poor or no antitumoral activity. The introduction of various chemicals such as chelating agents and/or transition metals within the growth medium of the bacteria improves the heating properties of the chains of magnetosomes. Moreover, the insertion of the chains of magnetosomes within a lipid vesicle is also suggested in order to favor their rotation in vivo and hence to improve their heating capacity. The vesicle can contain an antitumoral agent together with the chains of magnetosomes, and the agent is released within the tumors by heating the vesicle.

IPC Classes  ?

  • A61N 1/40 - Applying electric fields by inductive or capacitive coupling
  • A61N 2/00 - Magnetotherapy
  • A61K 35/74 - Bacteria
  • C12N 1/20 - BacteriaCulture media therefor
  • C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/10 - DispersionsEmulsions
  • A61K 9/51 - Nanocapsules
  • A61K 33/26 - IronCompounds thereof

32.

PARTICLE COMPRISING AT LEAST ONE FERRIMAGNETIC OR FERROMAGNETIC IRON OXIDE NANOPARTICLE ASSOCIATED WITH AT LEAST ONE COMPOUND FOR MEDICAL OR COSMETIC USE

      
Document Number 02996378
Status In Force
Filing Date 2016-10-21
Open to Public Date 2017-04-27
Grant Date 2023-06-27
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Chebbi, Imene

Abstract

The invention relates to the use, particularly in vitro, of a particle as a probe, said particle comprising: at least one ferrimagnetic or ferromagnetic iron oxide nanoparticle (NANOF) associated with at least one compound, in which the compound breaks away from the iron oxide nanoparticle and/or is altered chemically following a physico-chemical disturbance exerted on the particle.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 49/00 - Preparations for testing in vivo
  • C09K 11/00 - Luminescent, e.g. electroluminescent, chemiluminescent, materials
  • G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

33.

APYROGENIC PREPARATION CONTAINING NANOPARTICLES SYNTHESISED BY MAGNETOTACTIC BACTERIA FOR MEDICAL OR COSMETIC APPLICATIONS.

      
Document Number 02985163
Status In Force
Filing Date 2016-06-15
Open to Public Date 2016-12-22
Grant Date 2020-08-25
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Durand-Dubief, Mickael

Abstract

The present invention relates to an apyrogenic preparation containing nanoparticles synthesised by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles according to the invention consist of a central crystallised mineral portion mostly comprising an iron oxide, and a peripheral coating not comprising material originating from magnetotactic bacteria.

IPC Classes  ?

  • A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 33/26 - IronCompounds thereof
  • A61L 31/02 - Inorganic materials
  • A61L 31/08 - Materials for coatings
  • A61P 35/00 - Antineoplastic agents
  • C01G 49/02 - OxidesHydroxides
  • C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
  • C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
  • C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide

34.

Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field

      
Application Number 13510416
Grant Number 10238886
Status In Force
Filing Date 2010-11-18
First Publication Date 2012-11-29
Grant Date 2019-03-26
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Faure, Stéphanie
  • Chebbi, Imène

Abstract

A method for the treatment of tumor(s) or tumor cell(s) or cancer(s) in a subject in need by the generation of heat. The latter is produced by chains of magnetosomes extracted from whole magnetotactic bacteria and subjected to an alternating magnetic field. These chains of magnetosomes yield efficient antitumoral activity whereas magnetosomes unbound from the chains or kept within the whole bacteria produce poor or no antitumoral activity. The introduction of various chemicals such as chelating agents and/or transition metals within the growth medium of the bacteria improves the heating properties of the chains of magnetosomes. Moreover, the insertion of the chains of magnetosomes within a lipid vesicle is also suggested in order to favor their rotation in vivo and hence to improve their heating capacity. The vesicle can contain an antitumoral agent together with the chains of magnetosomes. In this case, the agent is released within the tumors by heating the vesicle.

IPC Classes  ?

  • A61N 1/40 - Applying electric fields by inductive or capacitive coupling
  • A61N 2/00 - Magnetotherapy
  • A61K 35/74 - Bacteria
  • C12N 1/20 - BacteriaCulture media therefor
  • C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/10 - DispersionsEmulsions
  • A61K 9/51 - Nanocapsules
  • A61K 33/26 - IronCompounds thereof

35.

USE OF CHAINS OF MAGNETOSOMES TO TREAT TUMORS BY HEAT THERAPY

      
Document Number 02780851
Status In Force
Filing Date 2010-11-18
Open to Public Date 2011-05-26
Grant Date 2016-12-13
Owner ALPHAONCO (France)
Inventor
  • Alphandery, Edouard
  • Faure, Stephanie
  • Chebbi, Imene

Abstract

In this disclosure, we describe a method for the treatment of tumor(s) or tumor cell(s) or cancer(s) in a subject in need by the generation of heat. The latter is produced by chains of magnetosomes extracted from whole magnetotactic bacteria and subjected to an alternative magnetic field. These chains of magnetosomes yield efficient antitumoral activity whereas magnetosomes unbound from the chains or kept within the whole bacteria produce poor or no antitumoral activity. The introduction of various chemicals such as chelating agents and/or transition metals within the growth medium of the bacteria improves the heating properties of the chains of magnetosomes. Moreover, the insertion of the chains of magnetosomes within a lipid vesicle is also suggested in order to favor their rotation in vivo and hence to improve their heating capacity. The vesicle can contain an antitumoral agent together with the chains of magnetosomes. In this case, the agent is released within the tumors by heating the vesicle.

IPC Classes  ?